Company intelligence / Profile preview

Recurium

San Diego, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Recurium Therapeutics is a biotechnology company focused on developing next-generation small molecule therapeutics for previously undruggable targets in oncology and other serious diseases. The company utilizes a proprietary drug discovery platform that combines advanced chemical biology, high-throughput screening, and computational tools to identify novel binders for challenging proteins such as transcription factors and RNA-binding proteins. Founded by pioneers from Scripps Research, Recurium aims to translate complex biological insights into transformative medicines. Their current pipeline is primarily focused on high-impact oncogenic drivers, including the MYC and KRAS pathways.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Recurium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recurium.

Explore the full profile